VANCOUVER, British Columbia, Canada, Sept. 22, 2003 (PRIMEZONE) -- ProtoKinetix, Inc. is pleased to announce the appointment of Dr. Ricardo Moro-Vidal to its Scientific Advisory Board. Dr. Moro discovered the universal cancer marker RECAF and is CEO of BioCurex, Inc.
Relating to the appointment, Dr. Moro stated, "I am very honored by this appointment. ProtoKinetix has a very novel approach to cancer therapy that is not covered by BioCurex's patents. Therefore, by combining our efforts, we can build a synergistic relationship that will benefit both our companies and cancer patients as well."
The Company added, "Dr. Moro's unquestioned expertise will be invaluable in the development of a RECAF-based cancer therapy, under license from BioCurex Inc."
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission. Specifically, investors should be cautious as ProtoKinetix, Incorporated is presently a development stage biotechnology company with limited financial resources. This presents significant risk to investors. Existing and prospective investors should undertake a thorough due diligence process, as well as seek advice from a registered securities broker before considering an investment in this company.